Higher Patient Satisfaction Reported With Switch to Triumeq from Existing ART
Recently-published data evaluated the safety, efficacy, and tolerability of switching from an antiretroviral therapy (ART) to once-daily abacavir/dolutegravir/lamivudine (Triumeq, ViiV Healthcare).